Europe — EMA
Navelbine (Vinorelbine)
GNH USA supplies Navelbine (Vinorelbine), a Vinca alkaloid for non‑small cell lung cancer and metastatic breast cancer. Request a quote for global supply.
Request sourcing
What is Vinorelbine?
Vinorelbine, the active ingredient in Navelbine, is a Vinca alkaloid presented as an oral formulation for oral use. It treats non‑small cell lung cancer and metastatic breast cancer in adult patients.
GNH USA supplies Navelbine as a licensed, GDP-compliant international pharmaceutical supplier serving oncology centres worldwide.
What is Vinorelbine used for?
Vinorelbine is employed in the treatment of solid tumours, particularly within the lung and breast cancer pathways.
- Non‑small cell lung cancer: improves disease control and prolongs survival in adult patients. - Metastatic breast cancer: provides tumour response and disease stabilization in advanced disease.
What are the side effects of Vinorelbine?
Vinorelbine may cause a range of adverse reactions that vary in frequency and severity.
Common Side Effects: - Nausea and vomiting - Neutropenia - Anemia - Constipation - Fatigue - Alopecia
Serious or Rare Side Effects: - Febrile neutropenia with infection risk - Severe pulmonary toxicity (e.g., interstitial pneumonitis) - Peripheral neuropathy - Life‑threatening allergic reactions - Cardiac arrhythmias - Severe hepatic dysfunction
What precautions apply to Vinorelbine?
When using Vinorelbine, clinicians should observe several safety measures.
- Monitor blood counts: perform regular complete blood count assessments. - Assess liver function: evaluate hepatic enzymes before and during therapy. - Adjust for renal impairment: use caution in patients with severe renal dysfunction. - Caution with neuropathy: avoid or reduce dose in patients with pre‑existing peripheral neuropathy. - Avoid concurrent myelosuppressive agents unless clinically justified. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.
What does Vinorelbine interact with?
Vinorelbine can interact with other medicines, requiring careful management.
Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) - Concurrent myelosuppressive chemotherapy agents - Radiotherapy to the same treatment field - Drugs that significantly prolong QT interval
Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine) - Anticoagulants (e.g., warfarin) due to platelet effects - Other antineoplastic agents with overlapping toxicity - Medications affecting hepatic metabolism - Herbal supplements such as St. John’s wort
